Purpose: Thus, this overview aimed to answer the focused question: “What is the evidence from systematic reviews on the treatment of patients with DDwoR of the TMJ?”. Methods: This overview was register on the Open Science Framework under osf.io/74cej. This study was performed according to The Joanna Briggs Institute Reviewers’ Manual 2014: Methodology for JBI Umbrella Reviews and Cochrane Handbook for Systematic Reviews of Interventions Version 6.2, using the following electronic databases: MEDLINE|PubMed, Web of Science, Cochrane Library, Embase, Scopus and LILACS|VHL, and other sources. Eligible articles were systematically reviewed and assessed for bias using preset criteria. The quality of evidence and the possibility of biased results from the included studies were independently assessed by two researchers using AMSTAR 2, OQAQ, CASP and ROBIS tools. Results: Five systematic reviews with meta-analyses and one qualitative review were included in this overview. Differences in pain control and improvement in mandibular function were observed between the treatments studied, especially for open surgery. However, the comparative effectiveness of conservative and invasive treatments for DDwoR remains uncertain due to the low methodological quality of the secondary studies analyzed in this overview and the risk of bias of the primary studies reported by the authors. Conclusions: Currently, it is not possible to guarantee the superiority of different DDwoR treatments to guide professionals and patients. This overview clarified the reason for the lack of consensus on which treatment is most effective for DDwoR and identified the low quality of evidence on the subject.

Background The aim of the present theoretical essay is to evaluate evidence published on the characteristics of the transcription of SARS-CoV-2 and explain the mechanism of action of ivermectin that may justify its therapeutic use in clinical practice for the treatment of COVID-19. Methods Laboratory studies, narratives, editorials and expert opinions on the subject were identified through a systematic search of the literature in the Medline/PubMed, Cochrane Library, Web of Science and Embase databases. Two blinded, independent reviewers selected studies published up to May 17, 2020 based on the eligibility criteria. Results The search of the databases led to the retrieval of 25 articles. After the different phases of the selection process, eight articles were included in the present review for the extraction of relevant data. The results suggest that ivermectin inhibits the viral replication of SARS-CoV-2 through the action of the hypoxia-inducible factor (HIF-1α) and consequent destabilization of importin α/β1 proteins. Conclusions Ivermectin inhibits the viral replication of SARS-CoV-2. Laboratory and clinical studies are needed to provide more evidence in terms of the best posology and possible associations with other drugs for combatting COVID-19.